Janone selects partner for bottling and labeling of jan101 for potential clinical trials

Janone selects partner for bottling and labeling of jan101 for peripheral artery disease and potential covid-19 clinical trials.janone inc - partnership to ensure clinical compliance for active and placebo dosing for pad phase 2b trials planned for early 2021.janone inc - expects to submit ind for treatment of covid-19 vascular complications in coming weeks.
JAN Ratings Summary
JAN Quant Ranking